Download Chapter 5 Cardiovascular Magnetic Resonance

THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
Chapter 5 Cardiovascular
Magnetic Resonance
Dudley J. Pennell, Udo P. Sechtem,
Sanjay Prasad, and Frank E. Rademakers
References
1 Manning WJ, Pennell DJ. Cardiovascular Magnetic Resonance,
2002. Philadelphia, PA: Churchill Livingstone.
2 Strohm O, Kivelitz D, Gross W, et al. Safety of implantable
coronary stents during H-1 magnetic resonance imaging at 1.0
and 1.5T. J Cardiovasc Magn Reson 1999; 1: 239–45.
3 Martin ET, Coman JA, Shellock FG, et al. Magnetic resonance
imaging and cardiac pacemaker safety at 1.5-Tesla. J Am Coll
Cardiol 2004; 43: 1315–24.
4 Grothues F, Smith GC, Moon JC, et al. Comparison of
interstudy reproducibility of cardiovascular magnetic
resonance with two-dimensional echocardiography in normal
subjects and in patients with heart failure or left ventricular
hypertrophy. Am J Cardiol 2002; 90: 29–34.
5 Grothues F, Moon JCC, Bellenger NG, et al. Interstudy
reproducibility of right ventricular volumes, function and mass
with cardiovascular magnetic resonance. Am Heart J 2004;
147: 218–23.
6 Maceira AM, Prasad SK, Khan M, et al. Normalized left
ventricular systolic and diastolic function by steady state free
precession cardiovascular magnetic resonance. J Cardiovasc
Magn Reson 2006; 8: 417–26.
7 Maceira AM, Prasad SK, Khan M, et al. Reference right
ventricular systolic and diastolic function normalized to age,
gender and body surface area from steady-state free precession
cardiovascular magnetic resonance. Eur Heart J 2006; 27:
2879–88.
8 Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive
diagnosis of ischemia-induced wall motion abnormalities
with the use of high-dose dobutamine stress MRI: comparison
with dobutamine stress echocardiography. Circulation 1999;
99: 763–70.
9 Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications
for cardiovascular magnetic resonance (CMR): Consensus
panel report. Eur Heart J 2004; 25: 1940–65.
10 Mahrholdt H, Wagner A, Judd RM, et al. Assessment of
myocardial viability by cardiovascular magnetic resonance
imaging. Eur Heart J 2002; 23: 602–19.
11 Thomson LEJ, Kim RJ, Judd RM. Magnetic resonance imaging
for the assessment of myocardial viability. J Magn Res Imaging
2004; 19: 771–88.
12 Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced
MRI and routine single photon emission computed
tomography (SPECT) perfusion imaging for detection of
subendocardial myocardial infarcts: an imaging study. Lancet
2003; 361: 374–9.
2nd edition
13 Barbier CE, Bjerner T, Johansson L, et al. Myocardial scars
more frequent than expected: magnetic resonance imaging
detects potential risk group. J Am Coll Cardiol 2006; 48: 765–71.
14 Steen H, Merten C, Refle S, et al. Prevalence of different
gadolinium enhancement patterns in patients after heart
transplantation. J Am Coll Cardiol 2008; 52: 1160–7.
15 Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced
magnetic resonance imaging to identify reversible myocardial
dysfunction. N Engl J Med 2000; 343: 1445–53.
16 Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance
low-dose dobutamine test is superior to scar quantification for
the prediction of functional recovery. Circulation 2004; 109:
2172–4.
17 Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular
magnetic resonance predicts reversible myocardial dysfunction
and remodeling in patients with heart failure undergoing betablocker therapy. Circulation 2003; 108: 1945–53.
18 Paetsch I, Jahnke C, Wahl A, et al. Comparison of dobutamine
stress magnetic resonance, adenosine stress magnetic
resonance, and adenosine stress magnetic resonance perfusion.
Circulation 2004; 110: 835–42.
19 Kramer CM, Barkhausen J, Flamm SD, et al. Standardized
cardiovascular magnetic resonance imaging (CMR) protocols,
society for cardiovascular magnetic resonance: board of
trustees task force on standardized protocols. J Cardiovasc
Magn Reson 2008; 10: 35.
20 Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic
performance of stress cardiac magnetic resonance imaging in
the detection of coronary artery disease: a meta-analysis. J Am
Coll Cardiol 2007; 50: 1343–53.
21 Hundley WG, Morgan TM, Neagle CM, et al. Magnetic
resonance imaging determination of cardiac prognosis.
Circulation 2002; 106: 2328–33.
22 Dall’Armellina E, Morgan TM, Mandapaka S, et al. Prediction
of cardiac events in patients with reduced left ventricular
ejection fraction with dobutamine cardiovascular magnetic
resonance assessment of wall motion score index. J Am Coll
Cardiol 2008 July 22; 52: 279–86.
23 Kuijpers D, Ho KY, van Dijkman PR, et al. Dobutamine
cardiovascular magnetic resonance for the detection of
myocardial ischemia with the use of myocardial tagging.
Circulation 2003; 107: 1592–7.
24 Wahl A, Paetsch I, Gollesch A, et al. Safety and feasibility of
high-dose dobutamine-atropine stress cardiovascular magnetic
resonance for diagnosis of myocardial ischaemia: experience in
1000 consecutive cases. Eur Heart J 2004; 25: 1230–6.
25 Plein S, Kozerke S, Suerder D, et al. High spatial resolution
myocardial perfusion cardiac magnetic resonance for the
detection of coronary artery disease. Eur Heart J 2008; Jul 18.
[Epub ahead of print]
26 Costa MA, Shoemaker S, Futamatsu H, et al. Quantitative
magnetic resonance perfusion imaging detects anatomic and
physiologic coronary artery disease as measured by coronary
angiography and fractional flow reserve. J Am Coll Cardiol
2007; 50: 514–22.
27 Wolff SD, Schwitter J, Coulden R, et al. Myocardial first-pass
perfusion magnetic resonance imaging: a multicenter doseranging study. Circulation 2004; 110: 732–7.
© 2009 The European Society of Cardiology
Camm-Chap-05.indd 187
7/17/2009 5:56:57 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
28 Rosen BD, Lima JA, Nasir K, et al. Lower myocardial
perfusion reserve is associated with decreased regional left
ventricular function in asymptomatic participants of the
multi-ethnic study of atherosclerosis. Circulation 2006;
114: 289–97.
29 Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT:
comparison of perfusion-cardiac magnetic resonance
with single-photon emission computed tomography for
the detection of coronary artery disease in a multicentre,
multivendor, randomized trial. Eur Heart J 2008; 29: 480–9.
30 Fieno DS, Shea SM, Li Y, et al. Myocardial perfusion imaging
based on the blood oxygen level-dependent effect using
T2-prepared steady-state free-precession magnetic resonance
imaging. Circulation 2004; 110: 1284–90.
31 Plein S, Greenwood JP, Ridgway JP, et al. Assessment of nonST-segment elevation acute coronary syndromes with cardiac
magnetic resonance imaging. J Am Coll Cardiol 2004; 44:
2173–81.
32 Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac
magnetic resonance stress tests: adenosine stress perfusion
and dobutamine stress wall motion imaging. Circulation 2007;
115: 1769–76.
33 Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal
subendocardial perfusion in cardiac syndrome X detected by
cardiovascular magnetic resonance imaging. N Engl J Med
2002; 346: 1948–53.
34 Lanza GA, Buffon A, Sestito A, et al. Relation between stressinduced myocardial perfusion defects on cardiovascular
magnetic resonance and coronary microvascular dysfunction
in patients with cardiac syndrome X. J Am Coll Cardiol 2008;
51: 466–72.
35 Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting
acute coronary syndrome in the emergency department
with cardiac magnetic resonance imaging. Circulation 2003;
107: 531–7.
36 Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the
diagnosis and treatment of non-ST-segment elevation acute
coronary syndromes: The Task Force for the Diagnosis and
Treatment of Non-ST-Segment Elevation Acute Coronary
Syndromes of the European Society of Cardiology. Eur Heart J
2007; 28: 1598–660.
37 Plein S, Greenwood JP, Ridgway JP, et al. Assessment of nonST-segment elevation acute coronary syndromes with cardiac
magnetic resonance imaging. J Am Coll Cardiol 2004; 44:
2173–81.
38 Greenwood JP, Younger JF, Ridgway JP, et al. Safety and
diagnostic accuracy of stress cardiac magnetic resonance
imaging vs exercise tolerance testing early after acute ST
elevation myocardial infarction. Heart 2007; 93: 1363–8.
39 Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis
of negative adenosine stress magnetic resonance in patients
presenting to an emergency department with chest pain. J Am
Coll Cardiol 2006; 47: 1427–32.
40 Cury RC, Shash K, Nagurney JT, et al. Cardiac magnetic
resonance with T2-weighted imaging improves detection
of patients with acute coronary syndrome in the emergency
department. Circulation 2008; 118: 837–44.
2nd edition
41 Assomull RG, Lyne JC, Keenan N, et al. The role of
cardiovascular magnetic resonance in patients presenting
with chest pain, raised troponin, and unobstructed coronary
arteries. Eur Heart J 2007; 28: 1242–9.
42 Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed
enhancement and T2-weighted cardiovascular magnetic
resonance imaging differentiate acute from chronic myocardial
infarction. Circulation 2004; 109: 2411–16.
43 Friedrich MG, Abdel-Aty H, Taylor A, et al. The salvaged area
at risk in reperfused acute myocardial infarction as visualized
by cardiovascular magnetic resonance. J Am Coll Cardiol 2008;
51: 1581–7.
44 Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete
microinfarction after percutaneous coronary intervention
associated with mild creatine kinase-MB elevation. Circulation
2001; 103: 2780–3.
45 Mollet NR, Dymarkowski S, Volders W, et al. Visualization
of ventricular thrombi with contrast-enhanced magnetic
resonance imaging in patients with ischemic heart disease.
Circulation 2002; 106: 2873–6.
46 Johnson KR, Patel SJ, Whigham A, et al. Three-dimensional,
time-resolved motion of the coronary arteries. J Cardiovasc
Magn Reson 2004; 6: 663–73.
47 Paetsch I, Jahnke C, Barkhausen J, et al. Detection of coronary
stenoses with contrast enhanced, three-dimensional free
breathing coronary MR angiography using the gadoliniumbased intravascular contrast agent gadocoletic acid (B-22956).
J Cardiovasc Magn Reson 2006; 8: 509–16.
48 Sakuma H, Ichikawa Y, Chino S, et al. Detection of
coronary artery stenosis with whole-heart coronary magnetic
resonance angiography. J Am Coll Cardiol 2006; 48:
1946–50.
49 le Polain de Waroux JB, Pouleur AC, Goffinet C, et al.
Combined coronary and late-enhanced multidetectorcomputed tomography for delineation of the etiology
of left ventricular dysfunction: comparison with
coronary angiography and contrast-enhanced cardiac
magnetic resonance imaging. Eur Heart J 2008; 29:
2544–51.
50 Kim WY, Danias PG, Stuber M, et al. Coronary magnetic
resonance angiography for the detection of coronary stenoses.
N Engl J Med. 2001; 345: 1863–9.
51 Kim WY, Astrup AS, Stuber M, et al. Subclinical coronary and
aortic atherosclerosis detected by magnetic resonance imaging
in type 1 diabetes with and without diabetic nephropathy.
Circulation 2007; 115: 228–35.
52 Taylor AM, Thorne SA, Rubens MB, et al. Coronary artery
imaging in grown up congenital heart disease: complementary
role of magnetic resonance and x-ray coronary angiography.
Circulation 2000; 101: 1670–8.
53 Langerak SE, Kunz P, Vliegen HW, et al. MR flow mapping in
coronary artery bypass grafts: a validation study with Doppler
flow measurements. Radiology 2002; 222: 127–35.
54 Mavrogeni S, Papadopoulos G, Douskou M, et al. Magnetic
resonance angiography is equivalent to X-ray coronary
angiography for the evaluation of coronary arteries in Kawasaki
disease. J Am Coll Cardiol 2004; 43: 649–52.
© 2009 The European Society of Cardiology
Camm-Chap-05.indd 188
7/17/2009 5:56:57 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
55 Kim WY, Stuber M, Bornert P, et al. Three-dimensional
black-blood cardiac magnetic resonance coronary vessel wall
imaging detects positive arterial remodeling in patients with
nonsignificant coronary artery disease. Circulation 2002;
106: 296–9.
56 Wilensky RL, Song HK, Ferrari VA. Role of magnetic resonance
and intravascular magnetic resonance in the detection of
vulnerable plaques. J Am Coll Cardiol 2006; 47 (Suppl.8):
C48–C56.
57 Keenan NG, Locca D, Roughton M, et al. Magnetic resonance
of carotid artery aging in healthy subjects. Atherosclerosis 2008;
Nov 27. [Epub ahead of print.]
58 Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by
simvastatin induces regression of human atherosclerotic
lesions: two years' follow-up by high-resolution noninvasive
magnetic resonance imaging. Circulation 2002; 106: 2884–7.
59 Sorenson MB, Collins P, Ong PJL, et al. Long term use of
contraceptive depot medroxyprogesterone acetate in young
women impairs arterial endothelial function assessed by
cardiovascular magnetic resonance. Circulation 2002; 106:
1646–51.
60 Cai JM, Hatsukami TS, Ferguson MS, et al. Classification
of human carotid atherosclerotic lesions with in vivo
multicontrast magnetic resonance imaging. Circulation 2002;
106: 1368–73.
61 Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous
cap rupture with magnetic resonance imaging is highly
associated with recent transient ischemic attack or stroke.
Circulation 2002; 105: 181–5.
62 Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of
cardiac magnetic resonance imaging in the diagnosis of
hypertrophic cardiomyopathy. Circulation 2005; 112: 855–61.
63 Olivotto I, Maron MS, Autore C, et al. Assessment and
significance of left ventricular mass by cardiovascular magnetic
resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol
2008; 52: 559–66.
64 Abdel-Aty H, Cocker M, Strohm O, et al. Abnormalities in
T2-weighted cardiovascular magnetic resonance images of
hypertrophic cardiomyopathy: regional distribution and
relation to late gadolinium enhancement and severity of
hypertrophy. J Magn Reson Imaging 2008; 28: 242–5.
65 Moon JC, Fisher NG, McKenna WJ, et al. Detection of apical
hypertrophic cardiomyopathy by cardiovascular magnetic
resonance in patients with non–diagnostic echocardiography.
Heart 2004; 90: 645–9.
66 Maron MS, Hauser TH, Dubrow E, et al. Right ventricular
involvement in hypertrophic cardiomyopathy. Am J Cardiol
2007; 100: 1293–8.
67 Crilley JG, Boehm EA, Blair E, et al. Hypertrophic
cardiomyopathy due to sarcomeric gene mutations is
characterized by impaired energy metabolism irrespective of
the degree of hypertrophy. J Am Coll Cardiol 2003; 41: 1776–82.
68 Moon JCC, Reed E, Sheppard MA, et al. The histological basis
of late gadolinium enhancement cardiovascular magnetic
resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol
2004; 43: 2260–4.
2nd edition
69 Moon JCC, McKenna WJ, McCrohon JA, et al. Toward
clinical risk assessment in hypertrophic cardiomyopathy with
gadolinium cardiovascular magnetic resonance. J Am Coll
Cardiol 2003; 41: 1561–7.
70 Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and
frequency of arrhythmias in hypertrophic cardiomyopathy in
relation to delayed enhancement on cardiovascular magnetic
resonance. J Am Coll Cardiol 2008; 51: 1369–74.
71 Petersen SE, Jerosch-Herold M, Hudsmith LE, et al.
Evidence for microvascular dysfunction in hypertrophic
cardiomyopathy: new insights from multiparametric magnetic
resonance imaging. Circulation 2007; 115: 2418–25.
72 Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of
Anderson-Fabry disease in male patients with late onset
hypertrophic cardiomyopathy. Circulation 2002; 105: 1407–11.
73 Moon JCC, Sachdev B, Elkington AG, et al. Gadolinium
enhanced cardiovascular magnetic resonance in AndersonFabry disease: Evidence for a disease specific abnormality of the
myocardial interstitium. Eur Heart J 2003; 24: 2151–5.
74 Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme
replacement therapy on the cardiomyopathy of AndersonFabry disease: a randomised, double-blind, placebo-controlled
clinical trial of agalsidase alfa. Heart 2008; 94: 153–8.
75 McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of
heart failure related to dilated cardiomyopathy and coronary
artery disease using gadolinium-enhanced cardiovascular
magnetic resonance. Circulation 2003; 108: 54–9.
76 Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic
resonance, fibrosis, and prognosis in dilated cardiomyopathy.
J Am Coll Cardiol 2006; 48: 1977–85.
77 Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance
assessment of the substrate for inducible ventriclar tachycardia
in nonischemic cardiomyopathy. Circulation 2005; 112:
2821–5.
78 Soriano CJ, Ridocci F, Estornell J, et al. Late gadoliniumenhanced cardiovascular magnetic resonance identifies patients
with standardized definition of ischemic cardiomyopathy:
A single centre experience. Int J Cardiol 2007; 116: 167–73.
79 Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium
enhancement by cardiovascular magnetic resonance heralds an
adverse prognosis in nonischemic cardiomyopathy. J Am Coll
Cardiol 2008; 51: 2414–21.
80 Neubauer S, Horn M, Cramer M, et al. Myocardial
phosphocreatine to ATP ratio is a predictor of mortality in
patients with dilated cardiomyopathy. Circulation 1997; 96:
2190–6.
81 Modell B, Khan M, Darlison M. Survival in beta thalassaemia
major in the UK: Data from the UK Thalassaemia Register.
Lancet 2000; 355: 2051–2.
82 Anderson LJ, Westwood MA, Prescott E, et al. Development of
thalassaemic iron overload cardiomyopathy despite low liver
iron levels and meticulous compliance to desferrioxamine. Acta
Haematol 2006; 115: 106–8.
83 Westwood MA, Sheppard MN, Awogbade M, et al. Myocardial
biopsy and T2* magnetic resonance in heart failure due to
thalassemia. Br J Haematol 2005; 128: 2.
© 2009 The European Society of Cardiology
Camm-Chap-05.indd 189
7/17/2009 5:56:57 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
84 Anderson LJ, Holden S, Davies B, et al. Cardiovascular T2*
(T2 star) magnetic resonance for the early diagnosis of
myocardial iron overload. Eur Heart J 2001; 22: 2171–9.
85 Westwood M, Anderson LJ, Firmin DN, et al. A single breathhold multiecho T2* cardiovascular magnetic resonance
technique for diagnosis of myocardial iron overload. J Magn
Reson Imaging 2003; 18: 33–9.
86 Westwood M, Anderson LJ, Firmin DN, et al. Interscanner
reproducibility of cardiovascular magnetic resonance in the
early diagnosis of myocardial iron overload. J Magn Reson
Imaging 2003; 18: 616–20.
87 Westwood MA, Firmin DN, Gildo M, et al. Intercentre
reproducibility of magnetic resonance T2* measurements
of myocardial iron in thalassaemia. Int J Cardiovasc Imaging
2005; 21: 531–8.
88 Tanner MA, Galanello R, Dessi C, et al. Myocardial iron
loading in patients with thalassemia major on deferoxamine
chelation. J Cardiovasc Magn Reson 2006; 8: 543–7.
89 Daar S, Pathare AV, Jain R, et al. T2* cardiovascular magnetic
resonance in the management of thalassemia patients in
Oman. Haematologica 2009; 94: 140–1.
90 Au WY, Lam WW, Chu WW, et al. A cross-sectional
magnetic resonance imaging assessment of organ specific
hemosiderosis in 180 thalassemia major patients in Hong
Kong. Haematologica 2008; 93: 784–6.
91 Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac
magnetic resonance imaging R2* assessments and analysis of
historical parameters in patients with transfusion-dependent
thalassemia. Haematologica 2007; 92: 131–2.
92 Westwood MA, Anderson LJ, Maceira AM, et al. Normalized
left ventricular volumes and function in thalassemia major
patients with normal myocardial iron. J Magn Reson Imaging
2007; 25: 1147–51.
93 Westwood MA, Wonke B, Maceira AM, et al. Left ventricular
diastolic function compared with T2* cardiovascular magnetic
resonance for early detection of myocardial iron overload in
thalassemia major. J Magn Reson Imaging 2005; 22: 229–33.
94 Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron
clearance during reversal of siderotic cardiomyopathy with
intravenous desferrioxamine: A prospective study using T2*
cardiovascular magnetic resonance. Br J Haematol 2004;
127: 348–55.
95 Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized
controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial
siderosis. Blood 2006; 107: 3738–44.
96 Tanner MA, Galanello R, Dessi C, et al. A randomized,
placebo-controlled, double-blind trial of the effect of
combined therapy with deferoxamine and deferiprone on
myocardial iron in thalassemia major using cardiovascular
magnetic resonance. Circulation 2007; 115: 1876–84.
97 Tanner MA, Galanello R, Dessi C, et al. Combined chelation
therapy in thalassemia major for the treatment of severe
myocardial siderosis with left ventricular dysfunction. J
Cardiovasc Magn Reson 2008; 10: 12.
98 Modell B, Khan M, Darlison M, et al. Improved survival
of thalassaemia major in the UK and relation to T2*
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
2nd edition
cardiovascular magnetic resonance. J Cardiovasc Magn Reson
2008; 10: 42.
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac
morbidity and mortality in deferoxamine- or deferipronetreated patients with thalassemia major. Blood 2006; 107:
3733–7.
Telfer P, Coen PG, Christou S, et al. Survival of medically
treated thalassemia patients in Cyprus. Trends and risk factors
over the period 1980–2004. Haematologica 2006; 91: 1187–92.
Sen-Chowdhry S, Prasad SK, Syrris P, et al. Cardiovascular
magnetic resonance in arrhythmogenic right ventricular
cardiomyopathy revisited: Comparison with Task Force
Criteria and genotype. J Am Coll Cardiol 2006; 48: 2132–40.
Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive
detection of myocardial fibrosis in arrhythmogenic right
ventricular cardiomyopathy using delayed-enhancement
magnetic resonance imaging. J Am Coll Cardiol 2005; 45:
98–103.
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J
Med 2007; 357: 2153–65.
Smedema JP, Snoep G, van Kroonenburgh MP, et al.
Evaluation of the accuracy of gadolinium-enhanced CMR in
the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;
45: 1683–90.
Vignaux O, Dhote R, Duboc D, et al. Clinical significance of
myocardial magnetic resonance abnormalities in patients
with sarcoidosis: a 1-year follow-up study. Chest 2002; 122:
1895–901.
Shah KB, Inoue Y, Mehra MR. Amyloidosis and the
heart: a comprehensive review. Arch Intern Med 2006;
166: 1805–13.
Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular
magnetic resonance in cardiac amyloidosis. Circulation 2005;
111: 186–93.
Vogelsberg H, Mahrholdt H, Deluigi CC, et al.
Cardiovascular magnetic resonance in clinically suspected
cardiac amyloidosis: noninvasive imaging compared to
endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022–30.
Kohli SK, Pantazis AA, Shah JS, et al. Diagnosis of leftventricular non-compaction in patients with left-ventricular
systolic dysfunction: time for a reappraisal of diagnostic
criteria? Eur Heart J 2008; 29: 89–95.
Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left
ventricular non-compaction: insights from cardiovascular
magnetic resonance imaging. J Am Coll Cardiol 2005;
46: 101–5.
Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast
media enhanced magnetic resonance imaging visualises
myocardial changes in the course of viral myocarditis.
Circulation 1998; 97: 1802–9.
Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular
magnetic resonance assessment of human myocarditis: a
comparison to histology and molecular pathology. Circulation
2004; 109: 1250–8.
Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation,
patterns of myocardial damage, and clinical course of viral
myocarditis. Circulation 2006; 114: 1581–90.
© 2009 The European Society of Cardiology
Camm-Chap-05.indd 190
7/17/2009 5:56:57 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
114 Assomull RG, Lyne JC, Keenan N, et al. The role of
cardiovascular magnetic resonance in patients presenting
with chest pain, raised troponin, and unobstructed coronary
arteries. Eur Heart J 2007; 28: 1242–9.
115 Kilner PJ, Gatehouse PD, Firmin DN. Flow measurement by
magnetic resonance: a unique asset worth optimising.
J Cardiovasc Magn Reson 2007; 9: 723–8.
116 Baltes C, Hansen MS, Tsao J, et al. Determination of peak
velocity in stenotic areas: echocardiography versus k-t SENSE
accelerated MR Fourier velocity encoding. Radiology 2008;
246: 249–57.
117 Oosterhof T, van SA, Vliegen HW, et al. Preoperative
thresholds for pulmonary valve replacement in patients with
corrected tetralogy of Fallot using cardiovascular magnetic
resonance. Circulation 2007; 116: 545–51.
118 Kozerke S, Schwitter J, Pedersen EM, et al. Aortic and mitral
regurgitation: quantification using moving slice velocity
mapping. J Magn Reson Imaging 2001; 14: 106–12.
119 Caruthers SD, Lin SJ, Brown P, et al. Practical value of cardiac
magnetic resonance imaging for clinical quantification of
aortic valve stenosis: comparison with echocardiography.
Circulation 2003; 108: 2236–43.
120 Reant P, Lederlin M, Lafitte S, et al. Absolute
assessment of aortic valve stenosis by planimetry using
cardiovascular magnetic resonance imaging: comparison
with transesophageal echocardiography, transthoracic
echocardiography, and cardiac catheterisation. Eur J Radiol
2006; 59: 276–83.
121 Tanaka K, Makaryus AN, Wolff SD. Correlation of aortic
valve area obtained by the velocity-encoded phase contrast
continuity method to direct planimetry using cardiovascular
magnetic resonance. J Cardiovasc Magn Reson 2007; 9:
799–805.
122 Yap SC, van Geuns RJ, Meijboom FJ, et al. A simplified
continuity equation approach to the quantification of stenotic
bicuspid aortic valves using velocity-encoded cardiovascular
magnetic resonance. J Cardiovasc Magn Reson 2007; 9:
899–906.
123 Kon MW, Myerson SG, Moat NE, et al. Quantification of
regurgitant fraction in mitral regurgitation by cardiovascular
magnetic resonance: comparison of techniques. J Heart Valve
Dis 2004 July; 13: 600–7.
124 Shellock FG. Prosthetic heart valves and annuloplasty rings:
assessment of magnetic field interactions, heating, and artifacts
at 1.5 Tesla. J Cardiovasc Magn Reson 2001; 3: 317–24.
125 Masci PG, Dymarkowski S, Bogaert J. Valvular heart disease:
what does cardiovascular MRI add? Eur Radiol 2008; 18:
197–208.
126 Boxt LM, Rozenshtein A. MR imaging of congenital heart
disease. Magn Reson Imaging Clin N Am 2003; 11: 27–48.
2nd edition
127 Korperich H, Gieseke J, Barth P, et al. Flow volume and shunt
quantification in pediatric congenital heart disease by realtime magnetic resonance velocity mapping: a validation study.
Circulation 2004; 109: 1987–93.
128 Prasad SK, Soukias N, Hornung T, et al. Role of magnetic
resonance angiography in the diagnosis of major
aortopulmonary collateral arteries and partial anomalous
pulmonary venous drainage. Circulation 2004; 109: 207–14.
129 Frigiola A, Tsang V, Bull C, et al. Biventricular response after
pulmonary valve replacement for right ventricular outflow
tract dysfunction: is age a predictor of outcome? Circulation.
2008; 118 (Suppl.14): S182–S190.
130 Woodard PK, Bhalla S, Javidan-Nejad C, et al. Cardiac MRI
in the management of congenital heart disease in children,
adolescents, and young adults. Curr Treat Options Cardiovasc
Med 2008; 10: 419–24.
131 Kramer CM, Barkhausen J, Flamm SD, et al. Standardized
cardiovascular magnetic resonance imaging (CMR) protocols,
society for cardiovascular magnetic resonance: board of
trustees task force on standardized protocols. J Cardiovasc
Magn Reson 2008; 10: 35.
132 Ho VB. ACR appropriateness criteria on suspected
congenital heart disease in adults. J Am Coll Radiol 2008;
5: 97–104.
133 Crean A. Cardiovascular MR and CT in congenital heart
disease. Heart 2007; 93: 1637–47.
134 Narváez J, Narváez JA, Nolla JM, et al. Giant cell arteritis and
polymyalgia rheumatica: usefulness of vascular magnetic
resonance imaging studies in the diagnosis of aortitis.
Rheumatology 2005; 44: 479–83.
135 Weinsaft JW, Kim HW, Shah DJ, et al. Detection of left
ventricular thrombus by delayed-enhancement cardiovascular
magnetic resonance prevalence and markers in patients
with systolic dysfunction. J Am Coll Cardiol 2008; 52: 148–57.
136 Shiga T, Wajima Z, Apfel CC, et al. Diagnostic accuracy
of transesophageal echocardiography, helical computed
tomography, and magnetic resonance imaging for suspected
thoracic aortic dissection: systematic review and meta-analysis.
Arch Intern Med 2006; 166: 1350–6.
137 Ersoy H, Goldhaber SZ, Cai T, et al. Time-resolved MR
angiography: a primary screening examination of patients
with suspected pulmonary embolism and contraindications to
administration of iodinated contrast material. Am J Roentgenol
2007; 188: 1246–54.
138 Masui T, Finck S, Higgins CB. Constrictive pericarditis and
restrictive cardiomyopathy: evaluation with MR imaging.
Radiology 1992; 182: 369–73.
139 Fieno DS, Saouaf R, Thomson LE, et al. Cardiovascular
magnetic resonance of primary tumors of the heart: A review.
J Cardiovasc Magn Reson 2006; 8: 839–53.
© 2009 The European Society of Cardiology
Camm-Chap-05.indd 191
7/17/2009 5:56:57 PM